FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 239 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell... March 15, 2021 Reflections May 26, 2021 Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... June 30, 2021 Cancer Research UK announces appointment of new Chair March 28, 2023 Load more HOT NEWS FDA Approves New and Updated Indications for Temozolomide Under Project Renewal EMA Recommends Granting a Marketing Authorisation for Toripalimab Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a... Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and...
